Biotech · Private company
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Track this companyFree. Adds Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) to your Dealase workspace and tells you when its record changes.
Clinical trials61 recruiting or active
Pipeline programs11From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline11
- Companion diagnostic ( CDx)Phase 2 · Diffuse Cutaneous Systemic SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- Companion Diagnostic (CDx)Phase 2 · Crohn DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Companion Diagnostic (CDx) TestingPhase 2 · Ulcerative ColitisClinicalTrials.gov · fetched Nov 12, 2026
- TulisokibartPhase 2 · Crohn DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- TulisokibartPhase 2 · Ulcerative ColitisClinicalTrials.gov · fetched Nov 12, 2026
- TulisokibartPhase 2 · Diffuse Cutaneous Systemic SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- PRA023Phase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- PRA023 IV High DosePhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- PRA023 IV Low DosePhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- PRA023 SCPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- PRA052Phase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- A Study of PRA052 in Healthy VolunteersPHASE1 · COMPLETED · started Nov 7, 2022ClinicalTrials.gov NCT05603182 · fetched Nov 12, 2026
- Bioavailability of SC Formulation and Japanese Ethnobridging Study for PRA023PHASE1 · COMPLETED · started Apr 6, 2022ClinicalTrials.gov NCT05354349 · fetched Nov 12, 2026
- Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)PHASE2 · ACTIVE_NOT_RECRUITING · started Mar 29, 2022ClinicalTrials.gov NCT05270668 · fetched Nov 12, 2026
- A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn's Disease (MK-7240-006)PHASE2 · COMPLETED · started Jul 28, 2021ClinicalTrials.gov NCT05013905 · fetched Nov 12, 2026
- A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)PHASE2 · COMPLETED · started Jul 14, 2021ClinicalTrials.gov NCT04996797 · fetched Nov 12, 2026
- A Study of PRA023 in Healthy VolunteersPHASE1 · COMPLETED · started Dec 15, 2020ClinicalTrials.gov NCT04676178 · fetched Nov 12, 2026